Recombinant Human PD-1 /PDCD1 Protein
- Known as:
- Recombinant Human PD-1 /PDCD1 Protein
- Catalog number:
- pd-038
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Proxinobio
- Gene target:
- Recombinant Human PD-1 /PDCD1 Protein
Related genes to: Recombinant Human PD-1 /PDCD1 Protein
- Gene:
- AVEN NIH gene
- Name:
- apoptosis and caspase activation inhibitor
- Previous symbol:
- -
- Synonyms:
- PDCD12
- Chromosome:
- 15q14
- Locus Type:
- gene with protein product
- Date approved:
- 2002-09-17
- Date modifiied:
- 2016-10-05
- Gene:
- CD274 NIH gene
- Name:
- CD274 molecule
- Previous symbol:
- PDCD1LG1
- Synonyms:
- B7-H, B7H1, PD-L1, PDL1, B7-H1
- Chromosome:
- 9p24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-11-13
- Date modifiied:
- 2014-11-19
- Gene:
- CLA3 NIH gene
- Name:
- cerebellar ataxia 3 (cerebellar parenchyma disorder 1)
- Previous symbol:
- CPD1
- Synonyms:
- -
- Chromosome:
- reserved
- Locus Type:
- phenotype only
- Date approved:
- 1991-08-22
- Date modifiied:
- 2011-02-10
- Gene:
- CNBD2 NIH gene
- Name:
- cyclic nucleotide binding domain containing 2
- Previous symbol:
- C20orf152, CNMPD1
- Synonyms:
- dJ954P9.1
- Chromosome:
- 20q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 2001-07-17
- Date modifiied:
- 2012-11-15
- Gene:
- COMP NIH gene
- Name:
- cartilage oligomeric matrix protein
- Previous symbol:
- PSACH, EDM1, EPD1
- Synonyms:
- MED, THBS5
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-24
- Date modifiied:
- 2016-10-05
Related products to: Recombinant Human PD-1 /PDCD1 Protein
Related articles to: Recombinant Human PD-1 /PDCD1 Protein
- The current therapy cannot meet the needs of glioblastoma (GBM). V-domain immunoglobulin suppressor of T-cell activation (VISTA) is significantly up-regulated in GBM patients; however, its therapeutic potential in GBM is still unclear. - Source: PubMed
Publication date: 2024/12/03
Jin ShashaLi TaoLiu LiuGao TingZhang TingtingYuan DingyiDi JianwenGuo ZhanyingLuo ZhijieYuan HaoliangLiu Jun - The blockers of programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway have achieved great clinical success. However, the limited efficacy and low tumor response rate of anti-PD-1/PD-L1 monotherapy limit the clinical application of PD-1/PD-L1 inhibitors. V-domain immunoglobulin suppressor of T-cell activation (VISTA), a novel checkpoint regulator, exhibits potential synergy with PD-1/PD-L1 in enhancing antitumor immunity. Herein, we report the discovery of benzo[]oxazole as novel dual small-molecule inhibitors targeting PD-1/PD-L1 and VISTA with high PD-1/PD-L1 inhibitory activity and VISTA binding affinity. rescues the immunosuppression of T-cells mediated by PD-L1 and VISTA and activates antitumor immunity effectively. Moreover, could induce degradation of PD-L1 and VISTA in tumor cell. Furthermore, displays significant antitumor efficacy in a CT26 mouse model. Our results discover as a promising dual PD-1/PD-L1 and VISTA inhibitor, providing a novel therapeutic strategy to overcome the limitations of current anti-PD-1/PD-L1 therapy. - Source: PubMed
Publication date: 2024/10/10
Wang KaizhenCai ShiCheng YaoQi ZhihaoNi XiangZhang KuojunXiao YibeiZhang XiangyuWang Tianyu - Hormone receptor-positive breast cancer (HR BC) is known to be relatively insensitive to chemotherapy, and since chemotherapy has remained the major neoadjuvant therapy for HR BC, the undetermined mechanism of chemoresistance and how chemotherapy reshapes the immune microenvironment need to be explored by high-throughput technology. By using single-cell RNA sequencing and multiplexed immunofluorescence staining analysis of HR BC samples (paired pre- and post-neoadjuvant chemotherapy (NAC)), the levels of previously unrecognized immune cell subsets, including CD8 T cells with pronounced expression of T-cell development (LMNA) and cytotoxicity (FGFBP2) markers, CD4 T cells characterized by proliferation marker (ATP1B3) expression and macrophages characterized by CD52 expression, were found to be increased post-NAC, which were predictive of chemosensitivity and their antitumor function was also validated with in vitro experiments. In terms of immune checkpoint expression of CD8 T cells, we found their changes were inconsistent post-NAC, that LAG3, VSIR were decreased, and PDCD1, HAVCR2, CTLA4, KLRC1 and BTLA were increased. In addition, we have identified novel genomic and transcriptional patterns of chemoresistant cancer cells, both innate and acquired, and have confirmed their prognostic value with TCGA cohorts. By shedding light on the ecosystem of HR BC reshaped by chemotherapy, our results uncover valuable candidates for predicting chemosensitivity and overcoming chemoresistance in HR BC. - Source: PubMed
Publication date: 2024/01/23
Jia FangSun ShanshanLi JiaxinWang WenwenHuang HuanhuanHu XiaoxiaoPan ShengChen WuzhenShen LesangYao YaoZheng SiweiChen HailongXia WenjieYuan HongjunZhou JunYu XiuyanZhang TingZhang BingHuang JianNi Chao - Radiation injury is common after radiotherapy for head and neck cancer. Radiotherapy can reshape the immune microenvironment and cause immunosuppression, including dysregulation of immune checkpoints (ICs). However, the relationship between oral ICs expression after radiation and the development of second primary tumors is unclear. - Source: PubMed
Publication date: 2023/05/22
Wang LiWang SiyuZhang JiayuPeng JianminCheng BinLi HuanHu Qinchao - The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therapeutic option for cancer treatment. However, modulating the immune system with ICIs still faces obstacles with severe immunogenic side effects and a lack of response against many cancer types. Plant-derived natural compounds offer regulation on various signaling cascades and have been applied for the treatment of multiple diseases, including cancer. Accumulated evidence provides the possibility of efficacy of phytochemicals in combinational with other therapeutic agents of ICIs, effectively modulating immune checkpoint-related signaling molecules. Recently, several phytochemicals have been reported to show the modulatory effects of immune checkpoints in various cancers in in vivo or in vitro models. This review summarizes druggable immune checkpoints and their regulatory factors. In addition, phytochemicals that are capable of suppressing PD-1/PD-L1 binding, the best-studied target of ICI therapy, were comprehensively summarized and classified according to chemical structure subgroups. It may help extend further research on phytochemicals as candidates of combinational adjuvants. Future clinical trials may validate the synergetic effects of preclinically investigated phytochemicals with ICI therapy. - Source: PubMed
Publication date: 2021/07/27
Lee JuwonHan YoungjinWang WenyuJo HyunAKim HeeyeonKim SoochiYang Kyung-MinKim Seong-JinDhanasekaran Danny NSong Yong Sang